Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs.

Rossanna C Pezo Andrew T YanCraig EarleKelvin K Chan

Published in: Heart (British Cardiac Society) (2019)

Our study highlights common use of QT-prolonging drugs and underuse of ECG in oncology patients. Since ECG is an inexpensive, non-invasive and widely available test, it may be readily incorporated in the monitoring of patients for toxicities in routine clinical practice.

Keyphrases

end stage renal disease
clinical practice
ejection fraction
newly diagnosed
chronic kidney disease
heart rate variability
palliative care
peritoneal dialysis
prognostic factors
drug induced
blood pressure